NASDAQ:CLYM Climb Bio (CLYM) Stock Price, News & Analysis $1.17 +0.02 (+1.74%) As of 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsTrendsBuy This Stock About Climb Bio Stock (NASDAQ:CLYM) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Climb Bio alerts:Sign Up Key Stats Today's Range$1.09▼$1.2050-Day Range$1.15▼$1.9952-Week Range$1.09▼$11.55Volume565,367 shsAverage Volume358,017 shsMarket Capitalization$78.95 millionP/E RatioN/ADividend YieldN/APrice Target$10.00Consensus RatingStrong Buy Company OverviewClimb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.Read More… Remove Ads Climb Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks59th Percentile Overall ScoreCLYM MarketRank™: Climb Bio scored higher than 59% of companies evaluated by MarketBeat, and ranked 417th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingStrong Buy Consensus RatingClimb Bio has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageClimb Bio has received no research coverage in the past 90 days.Read more about Climb Bio's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Climb Bio are expected to grow in the coming year, from ($1.57) to ($0.66) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Climb Bio is -0.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Climb Bio is -0.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioClimb Bio has a P/B Ratio of 0.30. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Climb Bio's valuation and earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for CLYM. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldClimb Bio does not currently pay a dividend.Dividend GrowthClimb Bio does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for CLYM. News and Social Media2.6 / 5News Sentiment0.72 News SentimentClimb Bio has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Climb Bio this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for CLYM on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Climb Bio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,571.00 in company stock.Percentage Held by InsidersOnly 3.20% of the stock of Climb Bio is held by insiders.Percentage Held by Institutions69.76% of the stock of Climb Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Climb Bio's insider trading history. Receive CLYM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Climb Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address CLYM Stock News HeadlinesClimb Bio appoints Kim Cobleigh Drapkin, Bo Cumbo to boardApril 2 at 9:56 AM | markets.businessinsider.comWhat is Leerink Partnrs' Forecast for Climb Bio Q2 Earnings?March 29, 2025 | americanbankingnews.comNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. April 4, 2025 | Porter & Company (Ad)Climb Bio Fueled Up with Cash, Poised for More Milestones in ’25 – Quarterly Update ReportMarch 27, 2025 | finance.yahoo.comClimb Bio to Present at the 24th Annual Needham Virtual Healthcare ConferenceMarch 27, 2025 | globenewswire.comClimb Bio Advances Clinical Trials and Expands PipelineMarch 27, 2025 | tipranks.comClimb Bio, Inc.: Climb Bio Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business UpdatesMarch 26, 2025 | finanznachrichten.deClimb Bio Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business UpdatesMarch 25, 2025 | globenewswire.comSee More Headlines CLYM Stock Analysis - Frequently Asked Questions How have CLYM shares performed this year? Climb Bio's stock was trading at $1.80 at the start of the year. Since then, CLYM shares have decreased by 35.0% and is now trading at $1.17. View the best growth stocks for 2025 here. How were Climb Bio's earnings last quarter? Climb Bio, Inc. (NASDAQ:CLYM) posted its quarterly earnings data on Tuesday, March, 25th. The company reported ($0.13) EPS for the quarter, beating analysts' consensus estimates of ($0.15) by $0.02. How do I buy shares of Climb Bio? Shares of CLYM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings3/25/2025Today4/04/2025Next Earnings (Estimated)5/21/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CLYM Previous SymbolNASDAQ:CLYM CIK1768446 Webclimbbio.com Phone866-857-2596FaxN/AEmployees9Year FoundedN/APrice Target and Rating Average Stock Price Target$10.00 High Stock Price Target$10.00 Low Stock Price Target$10.00 Potential Upside/Downside+769.6%Consensus RatingStrong Buy Rating Score (0-4)3.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($2.13) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-35,120,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-42.21% Return on Assets-41.39% Debt Debt-to-Equity RatioN/A Current Ratio57.73 Quick Ratio57.73 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.90 per share Price / Book0.29Miscellaneous Outstanding Shares67,475,000Free Float65,073,000Market Cap$77.60 million OptionableN/A Beta-0.10 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:CLYM) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Climb Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Climb Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.